Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).
fingolimod
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Mayzent: New Drug for Treatment of Secondary Progressive Multiple Sclerosis
Siponimod released by Novartis is an improved version of Gilenya.
